EGF-functionalized lipid-polymer hybrid nanoparticles of 5-fluorouracil and sulforaphane with enhanced bioavailability and anticancer activity against colon carcinoma.
active targeting
colon cancer
drug delivery
hybrid nanoparticles
quality by design
Journal
Biotechnology and applied biochemistry
ISSN: 1470-8744
Titre abrégé: Biotechnol Appl Biochem
Pays: United States
ID NLM: 8609465
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
15
09
2021
accepted:
30
10
2021
pubmed:
15
11
2021
medline:
1
11
2022
entrez:
14
11
2021
Statut:
ppublish
Résumé
The present research work describes development of dual drug-loaded lipid-polymer hybrid nanoparticles (LPHNPs) of anticancer therapeutics for the management of colon cancer. The epidermal growth factor (EGF)-functionalized LPHNPs coloaded with 5-fluorouracil (FU) and sulforaphane (SFN) were prepared by one-step nanoprecipitation method. Box-Behnken design was applied for optimizing the material attributes and process parameters. The optimized LPHNPs revealed particle size 198 nm, polydispersity index 0.3, zeta potential -25.3 mV, and drug loading efficiency 19-20.3% for 5-FU and SFN, respectively. EGF functionalization on LPHNPs was confirmed from positive magnitude of zeta potential to 21.3 mV as compared with the plain LPHNPs. In vitro drug release performance indicated sustained and non-Fickian mechanism release nature of the drugs from LPHNPs. Anticancer activity evaluation in HCT-15 colon cancer cells showed significant reduction (p < 0.001) in the cell growth and cytotoxicity of the investigated drugs from various treatments in the order: EGF-functionalized LPHNPs > plain LPHNPs > free drug suspensions. Overall, the research work corroborated improved treatment efficacy of EGF-functionalized LPHNPs for delivering chemotherapeutic agents for the management of colon carcinoma.
Substances chimiques
Polymers
0
Fluorouracil
U3P01618RT
sulforaphane
GA49J4310U
Epidermal Growth Factor
62229-50-9
Lipids
0
Drug Carriers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2205-2221Informations de copyright
© 2021 International Union of Biochemistry and Molecular Biology, Inc.
Références
Xu R, Zhou B, Fung PC, Li X Recent advances in the treatment of colon cancer. Histol Histopathol 2006;21:867-72.
Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, et al. Colon cancer. Crit Rev Oncol Hematol 2010;74:106-33. https://doi.org/10.1016/j.critrevonc.2010.01.010
Barkat HA, Das SS, Barkat MA, Beg S, Hadi HA. Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress. Future Oncol 2020;16:2959-79. https://doi.org/10.2217/fon-2020-0198.
Banerjee A, Pathak S, Subramanium VD, G D, Murugesan R, Verma RS. Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discov Today 2017;22:1224-32. https://doi.org/10.1016/j.drudis.2017.05.006
Mathur P., Rawal S., Patel B., Patel M. M. Oral Delivery of Anticancer Agents Using Nanoparticulate Drug Delivery System. Current Drug Metabolism. 2020;20: (14):1132-1140. http://doi.org/10.2174/1389200220666191007154017
Beg S, Barkat MA, Ahmad FJ. Advancement in polymer and lipid-based nanotherapeutics for cancer drug targeting. Curr Pharm Des 2020;26: 1127-.
Swain S, Sahu PK, Beg S, Babu SM. Nanoparticles for cancer targeting: current and future directions. Curr Drug Deliv 2016;13:1290-302.
Rahman M, Beg S. Hitting the target: refining anticancer nanomedicine development. Eur Pharm Rev 2019;24:2-4.
Naeem M, Awan UA, Subhan F, Cao J, Hlaing SP, Lee J, et al. Advances in colon-targeted nano-drug delivery systems: challenges and solutions. Arch Pharm Res 2020;43:153-69. https://doi.org/10.1007/s12272-020-01219-0
Belali N, Wathoni N, Muchtaridi M. Advances in orally targeted drug delivery to colon. J Adv Pharm Technol Res 2019;10:100-6. https://doi.org/10.4103/japtr.JAPTR_26_19
Pardini B, Kumar R, Naccarati A, Novotny J, Prasad RB, Forsti A, et al. 5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes. Br J Clin Pharmacol 2002;72:162-3. https://doi.org/10.1111/j.1365-2125.2010.03892.x
Milano Gr, Chamorey A-L. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 2002;19:177-89. https://doi.org/10.1081/cbi-120002597
Zhang N, Yin Y, Xu S-J, Chen W-S. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 2008;13:1551-69. https://doi.org/10.3390/molecules13081551
Su X, Jiang X, Meng L, Dong X, Shen Y, Xin Y. Anticancer activity of sulforaphane: the epigenetic mechanisms and the nrf2 signaling pathway. Oxid Med Cell Longev 2018;2018: 5438179-, https://doi.org/10.1155/2018/5438179
Liang J, Hansch GM, Hubner K, Samstag Y. Sulforaphane as anticancer agent: a double-edged sword? Tricky balance between effects on tumor cells and immune cells. Adv Biol Regul 2019;71:79-87. https://doi.org/10.1016/j.jbior.2018.11.006
Tahata S, Singh SV, Lin Y, Hahm E-R, Beumer JH, Christner SM; et al. Evaluation of biodistribution of sulforaphane after administration of oral broccoli sprout extract in melanoma patients with multiple atypical nevi. Cancer Prev Res 2018;11, 429, https://doi.org/10.1158/1940-6207.capr-17-0268
Rahman M, Alharbi KS, Alruwaili NK, Anfinan N, Almalki WH, Padhy I, et al. Nucleic acid-loaded lipid-polymer nanohybrids as novel nanotherapeutics in anticancer therapy. Expert Opin Drug Deliv 2020;17:805-16. https://doi.org/10.1080/17425247.2020.1757645
Swain S, Sahu PK, Beg S, Babu SM. Nanoparticles for cancer targeting: current and future directions. Curr Drug Deliv 2016;12:1290-302.
Ferreira Soares DC, Domingues SC, Viana DBa, Tebaldi ML. Polymer-hybrid nanoparticles: current advances in biomedical applications. Biomed Pharmacother 2020;131: 110695, https://doi.org/10.1016/j.biopha.2020.110695
Hadinoto K, Sundaresan A, Cheow WS. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm 2013;85:427-43. https://doi.org/10.1016/j.ejpb.2013.07.002
Beg S, Almalki WH, Khatoon F, Alharbi KS, Alghamdi S, Akhter MH, et al. Lipid/polymer-based nanocomplexes in nucleic acid delivery as cancer vaccines. Drug Discov Today 2021;26:1891-903. https://doi.org/10.1016/j.drudis.2021.02.013
Mukherjee A, Waters AK, Kalyan P, Achrol AS, Kesari S, Yenugonda VM. Lipid-polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives. Int J Nanomed 2019;14:1937-52. https://doi.org/10.2147/ijn.s198353
Beg S, Rahman M, Kohli K. Quality-by-design approach as a systematic tool for the development of nanopharmaceutical products. Drug Discov Today 2019;24:717-25. https://doi.org/10.1016/j.drudis.2018.12.002
Beg S, Hasnain MS, Rahman M, Swain S Chapter 1 - Introduction to quality by design (QbD): fundamentals, principles, and applications. In Pharmaceutical Quality by Design; Academic Press: 2019; pp. 1-17.
Wu M, Fan Y, Lv S, Xiao B, Ye M, Zhu X. Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery. Drug Deliv 2016;23:2720-5, https://doi.org/10.3109/10717544.2015.1058434
Kebebe D, Wu Y, Zhang B, Yang J, Liu Y, Li X, et al. Dimeric c(RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancer. Int J Nanomed 2019;14:6179-95, https://doi.org/10.2147/ijn.s202424
Fujioka T, Boivin S. Dialysis as a new pre-treatment technique for online bacterial counting. Sci Total Environ 2020;714: 136768, https://doi.org/10.1016/j.scitotenv.2020.136768
Prabhu D, Arulvasu C, Babu G, Manikandan R, Srinivasan P. Biologically synthesized green silver nanoparticles from leaf extract of Vitex negundo L. induce growth-inhibitory effect on human colon cancer cell line HCT15. Process Biochem 2012;48:317-24, https://doi.org/10.1016/j.procbio.2012.12.013
Li J, Chen L, Liu N, Li S, Hao Y, Zhang X. EGF-coated nano-dendriplexes for tumor-targeted nucleic acid delivery in vivo. Drug Deliv 2015;23:1718-25, https://doi.org/10.3109/10717544.2015.1004381
Skoglund S, Hedberg J, Yunda E, Godymchuk A, Blomberg E, Odnevall Wallinder, I. Difficulties and flaws in performing accurate determinations of zeta potentials of metal nanoparticles in complex solutions-Four case studies. PLoS One 2017;12: e0181735-, https://doi.org/10.1371/journal.pone.0181735
Wang B, Sun L, Wen M, Tan Y, Almalki WH, Katouah H, et al. Nano lipidic carriers for codelivery of sorafenib and ganoderic acid for enhanced synergistic antitumor efficacy against hepatocellular carcinoma. Saudi Pharm J 2021;29:843-56, https://doi.org/10.1016/j.jsps.2021.06.006
Wang L, Wang X, Shen L, Alrobaian M, Panda SK, Almasmoum HA, et al. Paclitaxel and naringenin-loaded solid lipid nanoparticles surface modified with cyclic peptides with improved tumor targeting ability in glioblastoma multiforme. Biomed Pharmacother 2021;138: 111461, https://doi.org/10.1016/j.biopha.2021.111461
Beg S, Choudhry H, Zamzami MA, Alharbi KS, Rahman M, Singh B. Nanocolloidal lipidic carriers of olmesartan medoxomil surface-tailored with Concavalin-A for lectin receptor targeting. Nanomedicine 2018;13:3107-28, https://doi.org/10.2217/nnm-2018-0188
Wu P, Zhou Q, Zhu H, Zhuang Y, Bao J. Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon. BMC Cancer 2020;20:354, https://doi.org/10.1186/s12885-020-06803-7
Haggag YA, Osman MA, El-Gizawy SA, Goda AE, Shamloula MM, Faheem AM, et al. Polymeric nano-encapsulation of 5-fluorouracil enhances anti-cancer activity and ameliorates side effects in solid Ehrlich Carcinoma-bearing mice. Biomed Pharmacother 2018;105:215-24, https://doi.org/10.1016/j.biopha.2018.05.124
Ghasemi Toudeshkchouei M, Zahedi P, Shavandi A. Microfluidic-assisted preparation of 5-fluorouracil-loaded PLGA nanoparticles as a potential system for colorectal cancer therapy. Materials (Basel, Switzerland) 2020;13: 1483, https://doi.org/10.3390/ma13071483
Yamamoto S, Iwamaru Y, Shimizu Y, Ueda Y, Sato M, Yamaguchi K, et al. Epidermal growth factor-nanoparticle conjugates change the activity from anti-apoptotic to pro-apoptotic at membrane rafts. Acta Biomater 2019;88:383-91, https://doi.org/10.1016/j.actbio.2019.02.026
Creixell M, Herrera AP, Ayala V, Latorre-Esteves M, Pérez-Torres M, Torres-Lugo M, et al. Preparation of epidermal growth factor (EGF) conjugated iron oxide nanoparticles and their internalization into colon cancer cells. J Magn Magn Mater 2010;322:2244-50, https://doi.org/10.1016/j.jmmm.2010.02.019